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Abstract
Vascular injury and remodeling are common pathological sequelae of hypertension. Previous
studies have suggested that the renin-angiotensin system (RAS) acting through the type I (AT1)
angiotensin (AT1)-receptor promotes vascular pathology in hypertension. To study the role of
AT1-receptors in this process, we generated mice with cell-specific deletion of AT1-receptors in
VSMCs using Cre/Loxp technology. We crossed the SM22α-Cre transgenic mouse line expressing
Cre recombinase in smooth muscle cells with a mouse line bearing a conditional allele of the
Agtr1a gene (Agtr1a flox), encoding the major murine AT1-receptor isoform (AT1A). In SM22α-
Cre+Agtr1a flox/flox (SMKO) mice, AT1A-receptors were efficiently deleted from VSMCs in larger
vessels, but not from resistance vessels such as pre-glomerular arterioles. Thus, vasoconstrictor
responses to angiotensin II were preserved in SMKOs. To induce hypertensive vascular
remodeling, mice were continuously infused with angiotensin II for 4 weeks. During infusion of
angiotensin II, blood pressures increased significantly and to a similar extent in SMKOs and
controls. In control mice, there was evidence of vascular oxidative stress indicated by enhanced
nitrated tyrosine residues in segments of aorta; this was significantly attenuated in SMKOs.
Despite these differences in oxidative stress, the extent of aortic medial expansion induced by
angiotensin II infusion was virtually identical in both groups. Thus, vascular AT1A-receptors
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promote oxidative stress in the aortic wall but are not required for remodeling in angiotensin II-
dependent hypertension.
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Introduction
The renin-angiotensin system (RAS) is a principal regulator of blood pressure homeostasis;
dysregulation of this system commonly contributes to human hypertension.1, 2 Accordingly,
pharmacological inhibitors of the RAS including ACE inhibitors and ARBs can effectively
lower blood pressure in a significant proportion of patients with essential hypertension.3, 4
Moreover, these agents also attenuate end-organ damage, decreasing cardiovascular
morbidity and slowing the progression of chronic kidney injury.5, 6 It has been suggested
that RAS inhibitors provide protection against complications of hypertension beyond their
effects to lower blood pressure, indicating non-hemodynamic, cellular actions of angiotensin
II to promote tissue damage.7 However, in some clinical trials, end-organ protection by RAS
inhibition has been accompanied by more effective reduction of blood pressure.4, 8, 9
Moreover, studies in animal models have suggested that the anti-hypertensive actions of
RAS inhibitors are critical for preventing cardiac hypertrophy 10 and progressive kidney
injury.11
The vascular system is a major target of damage in hypertension. Expansion of arteries and
arterioles in the kidney, also called nephrosclerosis, is the most common renal pathological
lesion accompanying hypertension12 and is an important cause of chronic kidney disease in
African Americans.13 Vessel remodeling with changes in compliance is also seen in the
aorta and other vascular beds in hypertension14 where the RAS has potent actions to
influence vascular structure and function.15 For example, angiotensin II causes systemic
vasoconstriction by activation of AT1-receptors in VSMCs.16 Along with their effects on
vascular tone, AT1-receptors may also stimulate growth and hypertrophy of vascular smooth
muscle cells,17 thereby directly contributing to vascular remodeling in hypertension. It has
been suggested that non-hemodynamic actions of AT1-receptors, including enhanced
generation of reactive oxygen species (ROS) may promote changes in vascular structure that
perpetuate the development of hypertension.14 Furthermore, ARBs reverse vascular
remodeling in patients with hypertension suggesting a direct role for vascular AT1-receptors
in this process.18
Nonetheless, the precise role of AT1-receptors in individual tissues is difficult to discern
through experiments using pharmacological inhibitors or conventional gene targeting, where
actions of AT1-receptors are abrogated in all tissues, and changes in blood pressure may
further confound interpretations. Accordingly, we generated mice with cell-specific deletion
of AT1A-receptors from smooth muscle cells in conduit vessels that are subject to
hypertensive remodeling. During angiotensin II-dependent hypertension, we find reduced
oxidative stress in vascular segments lacking AT1A-receptors, but vascular remodeling is
unaffected.
Methods
Generation of experimental animals
A mouse line with a conditional Agtr1a allele was generated using homologous
recombination in embryonic stem cells as described (Gurley et al., submitted and
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Supplemental Data please see http://hyper.ahajournals.org).19 SM22α-Cre mice were
purchased from The Jackson Laboratory (stock number 004746). Mice were bred and
maintained in the AAALAC-accredited animal facilities at the Durham VA Medical Center
according to NIH guidelines. All of the animal studies were approved by the Durham
Veterans’ Affairs Medical Center Institutional Animal Care and Use Committee and
conducted in accordance with the National Institutes of Health Guide for the Care and Use
of Laboratory Animals. Animals had free access to standard rodent chow and water unless
specified. 8–12 week-old male mice and littermate controls were used for experiments.
Isolation of pre-glomerular vessels for receptor expression analysis
Afferent arterioles and interlobular arteries were isolated from kidneys using a modified iron
oxide-sieving technique according to Chatziantoniou et al.20, 21 The enriched preparation of
pre-glomerular arteries and arterioles was transferred to a tube containing RNAlater and
stored at 4°C for 24 hours, then at −80°C.
Measurement of AT1A mRNA levels and RT-PCR
Relative levels of mRNA for the AT1A-receptor in various tissues were determined by real
time RT-PCR with the ABI Prism 7700 sequence detection system as described.22 Tissues
were harvested and total RNA was isolated using TRI Reagent (Sigma-Aldrich) per the
manufacturer’s instructions. The number of copies of the PCR template in the starting
sample is calculated using the Sequence Detector Software (SDS) incorporated in the ABI
Prism 7700 Sequence Detector System. For each experimental sample, the amounts of the
target and of the endogenous control were determined from the appropriate standard curves
or ΔΔCT
Isometric force measurements in aortic and mesenteric rings
Aortic and mesenteric artery rings were mounted in a wire myograph as described
previously.23 Dose-response curves were generated for phenylephrine and Angiotensin II.
Forces are expressed as a percentage of the maximal response to phenylephrine, this was
equivalent between groups.
Assessment of acute vasoconstrictor responses
Our previous studies showed that vasoconstrictor responses to acute administration of
angiotensin II are almost completely extinguished in mice with complete AT1A receptor-
deficiency.24 Therefore, to determine the veracity of the deletion of vascular AT1A
receptors, we examined acute pressor responses to angiotensin II as described previously.24
At 5-min intervals, increasing doses (0.1, 1 and 10 μg/kg) of Angiotensin II (Sigma Aldrich)
or 10 μg/kg of epinephrine (Sigma Aldrich) were injected intravenously while intra-arterial
pressures were continuously monitored.
Blood pressure measurements in conscious mice
Blood pressures were measured in 8–12 week old male conscious SMKO and control mice
using radiotelemetry, as described previously.25 During the measurement period, mice were
housed in a monitoring room where quiet is maintained and no other experiments are
performed. Arterial blood pressures were collected, stored, and analyzed using Dataquest A.
R. T. software (version 4.0, Transoma Medical). Measurements were recorded over a ten-
second interval every five minutes at baseline and during twenty-one days while Ang II was
infused chronically (1000ng/kg/min) by osmotic mini-pump (Alzet).
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Analysis of oxidized amino acids in aortae
Following 28 days of angiotensin II infusion, thoracic aortae were dissected from control
and SMKO mice and immediately place in antioxidant buffer (100 μM diethylene tetramino
pentaacetic acid (metal chelator), 50 μM butylated hydroxytoluene (lipid soluble
antioxidant), 10μL/ml protease inhibitor (Halt™ Protease Inhibitor Cocktail, Pierce,
Rockford, IL) in 50 mM sodium phosphate buffer, pH 7.4) at −80C. Amino acids were
isolated from the acid hydrolysate using a solid-phase column (Supelclean ENVI ChromP
column, Supelco Inc., Bellefonte, PA) as described.26 Oxidized amino acids were quantified
by liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/
MS) using multiple reaction monitoring (MRM) mode. Under these chromatography
conditions, authentic compounds and isotopically labeled standards were base line-separated
and exhibited retention times identical to those of analytes derived from tissue samples. 3-
nitrotyrosine and dityrosine were detected by characteristic LC retention time and specific
ion transitions in the MRM mode. The ratio of the peak areas of the analyte with
corresponding 13C internal standard were utilized to quantify levels of oxidized amino acids
in tissue. Results are normalized to protein content of tyrosine, the precursor of 3-
nitrotyrosine and dityrosine.
Measurement of hydrogen peroxide production in aortae
Hydrogen Peroxide (H2O2) of freshly prepared thoracic aorta from both SMKO and controls
(n=3 for both) were measured with the Amplex Red H2O2 Assay Kit (Molecular Probes).
Thoracic aortae were harvested and adventitial tissue was dissected free in ice cold Krebs-
Henseleit buffer. After opening the aorta with scissors and washing out the blood, the aorta
was incubated in the reaction mixture for 60 minutes in the dark at 37°C. The supernatant
was then read in a fluorescent spectrophotometery according to the protocol provided by the
manufacturer. The fluorescent values were normalized to the protein content measured in
each sample (BioRad).
Measurement of medial thickness, medial area and luminal area of aortae
The extent of vascular pathology was assessed by measuring medial thickness of descending
thoracic aorta. 2 cm of descending aorta was dissected in animals that were fixed and
perfused with 4% paraformaldehyde and placed in 10% formalin overnight. 10μm sections
were obtained after paraffin embedding. Sections were stained with hematoxalin and eosin
and photographs were taken at 40× and 10X (Zeiss Axio Imager, QImaging MicroPublisher
5.0 MP colour camera). Medial thickness, medial area and luminal area of the aorta using 4
random sections throughout the specimen and was quantified using MetaMorph in a blinded
fashion.
Statistical analysis
The values for each parameter within a group are expressed as mean ± SEM. For
comparisons between control and SMKO groups, statistical significance was assessed using
an unpaired 2-tailed Student’s t test. A paired 2-tailed Student’s t test was used for
comparisons within groups. P values less than 0.05 were considered significant. For blood
pressure tracings measured over multiple days, two-way AVOVA was performed followed
by Bonferroni correction.
Results
Generation of mice with deletion of AT1-receptors from smooth muscle
We carried out successive intercrosses between the SM22α-Cre line and mice homozygous
for the conditional “floxed” Agtr1a allele (Agtr1aflox/flox) to generate SM22α-Cre+-
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Agtr1aflox/flox (SMKO) and SM22α-Cre−-Agtr1aflox/flox (Control) mice for experiments. To
confirm elimination of AT1A-receptors from various vascular beds, levels of expression for
AT1A-receptor mRNA were measured by real-time RT-PCR. Segments of aorta were
isolated from SMKO and control mice, and the adventitia and endothelium were removed by
dissection. As shown in Figure 1A, mRNA for the AT1A-receptor was easily detected in
aortae from control mice, but not from SMKOs (P<0.0005). Similarly, AT1A mRNA
expression in mesenteric arteries, with intact endothelium and adventitia, was decreased by
60% in SMKO mice compared to controls (P<0.05; Figure 1A). Thus, in SMKOs, AT1A-
receptors are efficiently eliminated from VSMCs in conduit vessels. Furthermore, no
difference was seen in the relatively low levels of AT1B-receptor expression in aorta
between the groups (Figure 1B).
Vasoconstrictor responses measured ex vivo
In order to functionally verify the efficiency of deletion of the AT1A-receptor from VSMCs,
the contractile response of isolated vessels was assessed ex vivo. Isometric force was first
measured after exposure to phenylephrine and then was independently measured to
angiotensin II. Forces are expressed as a percentage of the maximal response to
phenylephrine, which was equivalent between groups. As shown in Figure 2, the contractile
response to Ang II was significantly reduced by ≈75% in aortae from the SMKOs compared
to controls (P≤0.0005) consistent with the absence of AT1A-receptor mRNA depicted in
Figure 1A above. Similarly, there was a corresponding reduction of ≈65% in the mesenteric
artery segments from SMKO mice compared to controls (P≤0.05; Figure 2).
AT1A mRNA expression in resistance arteries
To examine AT1A-receptor expression in a preparation of resistance arteries, pre-glomerular
arterioles were isolated from kidneys using the iron oxide sieving technique 21. Based on
microscopic examination (Figure 3A) and augmented mRNA expression of VSMC markers
such as smooth muscle actin (Figure 3B), there was marked enrichment for pre-glomerular
vessels using this approach. However, unlike results with the aorta or mesenteric arteries,
expression of AT1A mRNA in pre-glomerular arterioles isolated from SMKOs was
preserved at levels that were not significantly different from controls indicating lack of
efficient excision of the floxed Agtr1a gene in these segments (P=NS; Figure 3C).
Acute responses to vasoconstrictors
We next compared acute vasoconstrictor responses in SMKOs and controls in vivo. As
shown in Figure 4, we observed robust acute vasoconstriction in the controls in response to
escalating doses of angiotensin II from 0.1–10 μg/kg. The magnitude of vasoconstriction
was dose-proportional and virtually identical in SMKOs and controls. Preservation of a
normal vasoconstrictor response to angiotensin II in the SMKOs is consistent with their
unmodified expression of AT1A-receptors in resistance vessels (Figure 3C).
Blood pressure homeostasis is not affected in SMKOs
Radiotelemetry units were implanted into 8–12 week old male SMKO and control mice in
order to measure blood pressure in the conscious, unrestrained state. Mean arterial pressures
measured over 5 days were virtually identical between SMKO and control mice fed a
normal-salt (0.4% NaCl) diet (116±2 vs. 116±1 mmHg; n=11 in each group). Moreover,
diurnal variation of blood pressure was not affected in SMKOs (data not shown).
Blood pressure responses in angiotensin II-dependent hypertension
The preceding studies suggest that AT1A-receptors are effectively deleted from VSMCs in
the aorta in SMKOs but their blood pressure responses to angiotensin II are preserved. Thus,
Sparks et al. Page 5













we reasoned that the SMKOs would be a useful model for separating the relative
contributions of hypertension from direct actions of AT1A-receptors in VSMCs to aortic
remodeling. In order to induce vascular remodeling, osmotic minipumps were implanted
subcutaneously to infuse angiotensin II at 1000 ng/kg/min, while blood pressures were
continuously monitored.27, 28 As shown in Figure 5, the blood pressure responses to chronic
angiotensin II infusion were very similar in the SMKOs and controls. MAP increased
significantly by ≈30 mm Hg in both groups and remained elevated to an equivalent extent
throughout the period of the infusion. Further, there was no difference in MAP between the
groups averaged for the duration of angiotensin II administration (157±6 mm Hg vs. 153±6
mm Hg).
Vascular Oxidative Stress
To examine levels of oxidative stress specifically in the vasculature, we assessed oxidation
of proteins in the vascular wall. To this end, we isolated vascular wall proteins from thoracic
aortic segments of control and SMKO mice. After hydrolyzing the proteins with acid, amino
acids were isolated as described previously.26, 29–31 We then determined the content of the
two oxidized amino acids, 3-nitrotyrosine and dityrosine, “molecular signatures”
characteristic of peroxynitrite-mediated oxidation, by isotope dilution liquid
chromatography tandem mass spectrometry (LC/ESI/MS/MS). As shown in Figures 6A and
B, increased levels of both 3-nitrotyrosine and dityrosine were detected in aortic segments
from control mice after angiotensin II infusion. This increase was significantly attenuated in
SMKOs by ≈50% for dityrosine (137±27 vs. 74±10μmol/mol tyrosine; P<0.05) by ≈80%
for 3-nitrotyrosine (7819±1676 vs. 1768±450 μmol/mol tyrosine; P<0.005). To examine
ROS generation in the vasculature, we measured local production of hydrogen peroxide
using amplex red in freshly prepared thoracic aortae from control and SMKO mice at
baseline. Hydrogen peroxide generation was significantly lower in aortic segments from
SMKO mice (0.59±0.4 μM/mg protein) than in controls (4.723±1.1 μM/mg protein;
P<0.05). Taken together, these data indicate that oxidative stress in the aortic wall is
significantly attenuated in the SMKOs.
Vascular responses in angiotensin II-dependent hypertension
To determine the extent of vascular remodeling associated with the angiotensin II infusion,
medial thickness and medial to luminal area ratio of thoracic aortic sections was measured
by morphometry. As shown in Figures 7, there were no differences between controls and
SMKOs at baseline, suggesting that the absence of AT1A-receptors in VSMCs does not
significantly impact normal development and structure of the aorta. Following 4 weeks of
angiotensin II infusion, there was significant remodeling of the aorta in control mice
reflected by an increase in medial thickness from 27.7±1.9 μm at baseline to 50.5±2.4 μm
(Figure 7E; P<0.0005) and an increase in medial-to-lumen ratio from 0.38±0.08 at baseline
to 0.67±0.03 (Figure 7F; P<0.05). Similar increases in medial expansion (26.6±2.9 μm vs.
47±4.6 μm; p<0.005) and medial-to-lumen ratio (0.36±0.07 vs. 0.62±0.05;P<0.05) were
seen in the SMKOs with angiotensin II infusion, such that after angiotensin II infusion, these
parameters were virtually identical in SMKOs and controls (Figures 7C, D, E, and F).
Discussion
Vascular remodeling and injury are typical features of end-organ damage from hypertension,
contributing to clinical morbidity and mortality.14 In the kidney, vascular lesions, interstitial
fibrosis and arteriosclerosis are the defining characteristics of hypertensive nephrosclerosis,
a common cause of chronic kidney disease.12 In larger vessels such as the aorta, vascular
remodeling in hypertension produces changes in compliance resulting in increased pulse
pressure, which has been associated with enhanced cardiovascular risk.32, 33 Medial
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thickening of the carotid artery has been similarly associated with increased cardiovascular
risk and is commonly used as a surrogate marker for vascular outcomes in clinical trials.34
The renin-angiotensin system (RAS) is a major determinant of vascular function and
pathology.35 For example, angiotensin II acting through the AT1-angiotensin receptor causes
potent vasoconstriction.16 This vasoconstrictor response is mediated by activation of
AT1-receptors in VSMCs, triggering increased intra-cellular calcium leading to myosin
phosphorylation.36 Along with these physiological effects, activation of the RAS also
promotes vascular remodeling in patients with hypertension.18 In smaller vessels, these
structural changes can have hemodynamic consequences.18, 37 Further, activation of the
RAS may also impact the development of atherosclerosis38 and aortic aneurysms.39 Many of
the vascular consequences of AT1-receptor activation seem to emanate from direct effects in
VSMCs but these have largely been characterized in cultured cell systems.40, 41 The precise
contribution of AT1-receptors in VSMCs to vascular physiology and pathology in vivo has
been difficult to define since pharmacological antagonists or conventional gene knockouts
lower blood pressure and produce broad inhibition of AT1-receptors across all tissues
including VSMCs. Accordingly, in order to examine their actions in isolation in the intact
animal, we developed a mouse model to eliminate expression of AT1A-receptors specifically
in smooth muscle using Cre-loxp technology.
To excise the floxed Agtr1a allele from smooth muscle, we used the Sm22α-Cre transgenic
mouse line expressing Cre recombinase under control of the promoter of the Sm22α gene.42
We found that AT1A-receptors were efficiently deleted from aorta and early branches of the
mesenteric arteries in SMKOs (Figure 1). However, there was little or no excision from
resistance vessels, reflected by preserved acute pressor responses to angiotensin II (Figure 4)
and normal levels of AT1A-receptor mRNA expression in pre-glomerular vessels isolated
from SMKO mice (Figure 3C). Furthermore, the extent of excision from small resistance
arteries could not be appreciably enhanced when the Sm22α-Cre transgene was crossed onto
an Agtr1aflox/null background (data not shown). While previous studies have suggested that
the Sm22α promoter drives expression in most smooth muscle lineages including VSMCs,
43–45 the levels of expression in small resistance vessels have not been clearly documented.
Our study indicates that deletion of a floxed allele from peripheral resistance vessels cannot
be efficiently accomplished using this Cre transgene. Nonetheless, since AT1A-receptors
were efficiently eliminated from VSMC in the aorta but were preserved in resistance
arteries, we reasoned that this SMKO model could be useful for separating the consequences
of elevated blood pressure from direct actions of AT1-receptors in VSMCs on aortic
remodeling during hypertension. Indeed, the extent of blood pressure elevation with
angiotensin II infusion was very similar in the SMKOs and controls (Figure 5).
One of the key pathways linked to AT1-receptors in VSMCs is the generation of reactive
oxygen species (ROS).46 In this regard, AT1-receptors activate NADPH oxidases (Nox1,
Nox4) in VSMCs47, 48 generating ROS such as superoxide anion and H2O2, which may
contribute to the pathogenesis of hypertension.41, 49 Furthermore, stimulation of ROS
production by AT1-receptors in cultured VSMCs has been associated with cellular
hypertrophy.50 To examine the capacity of AT1A-receptors to promote oxidative stress in
vivo, we compared indices of oxidative stress between SMKOs and controls before and
during chronic angiotensin II infusion. At baseline, we found reduced levels of hydrogen
peroxide production by isolated aortic segments from SMKOs compared to controls. In
addition, we found evidence for marked reductions in the levels of oxidized tyrosine
residues (Figure 6). Excess O2•− produced by NOX enzymes or uncoupled eNOS can form
hydrogen peroxide or react with NO• to form the highly reactive oxidant peroxynitrite.26, 51,
52
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Along with contributing to oxidative stress, this reaction extinguishes the beneficial actions
of NO in the vasculature. Moreover, peroxynitrite can oxidize tyrosine residues in the
vascular wall and this covalent alteration provides a footprint to assess the extent of
oxidative stress over time.53 Our findings of decreased 3-nitrotyrosine and dityrosine in
SMKOs after angiotensin II administration are consistent with decreased peroxynitirite
formation by either of these mechanisms.30, 26 Taken together, our data indicate a key role
for AT1-receptors in VSMCs to promote oxidative stress as evidenced by the profound
reduction in 3-nitrotyrosine and dityrosine in hypertension, independent of any concomitant
effects of elevated blood pressure per se.
As discussed above, there exists ample evidence suggesting that generation of ROS by AT1-
receptor activation in VSMCs may have direct consequences on vascular structure and
function. In this regard, a number of studies have shown that administration of potent anti-
oxidant agents can attenuate angiotensin II-dependent hypertension.54, 55 Our studies
suggest that reduced oxidative stress in large conduit arteries alone is not sufficient to lower
blood pressure. Instead, this may require more robust ROS inhibition in resistance arteries,
the CNS,56 and/or the kidney.10 Moreover, the absence of AT1A-receptors and the dramatic
diminution of oxidative stress in the aortic wall of the SMKOs did not result in detectable
attenuation of medial hypertrophy compared to controls (Figure 7). This indicates that direct
actions of AT1A-receptors in VSMCs including generation of oxidative stress are not
required to induce aortic remodeling in this setting and is consistent with previous reports
describing dissociations between levels of reactive oxygen species generation and cardiac or
aortic remodeling.57–59 Since the severity of hypertension was similar in SMKOs and
controls, we suggest that elevated blood pressure is the major mechanism driving medial
expansion in this setting. This is in line with previous studies by our group and others
documenting the dominant actions of blood pressure to drive end-organ damage in the heart
and vasculature.10, 60, 61
Perspectives
Other factors such as elevated blood pressure may play a dominant role in hypertensive
vascular remodeling since the extent of hypertension was very similar between the
groups in our study. Alternatively, AT1-receptor actions, including ROS generation, in
other cell lineages such as endothelium or circulating inflammatory cells may have
significant roles in hypertensive vascular remodeling. Furthermore, our studies do not
rule out the possibility that pathways linked to AT1-receptors in VSMCs may contribute
to the pathogenesis of more complex vascular lesions such as atherosclerosis or
aneurysms, where oxidative stress has also been implicated.62
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Figure 1. The AT1A-receptor is deleted from conduit vessels
(A) Real time PCR performed on aorta stripped of adventitia and endothelium showed that
mRNA for the AT1A-receptor was easily detected in aortae from control mice (black bars),
but not from SMKOs (white bars)(n ≥ 3, ***P<0.0005 vs. control). AT1A mRNA
expression in mesenteric arteries, with intact endothelium and adventitia, was decreased by
60% in SMKO mice compared to controls (n=5,*P<0.05). (B) No difference was seen in
AT1B-receptor expression in the aorta between SMKOs and controls (n=3, P=NS).
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Figure 2. VSMC-specific AT1A-receptor deletion leads to diminished acute vascular angiotensin
II responses in conduit vessels ex vivo
Isometric force was measured in abdominal aorta and mesenteric artery ex vivo in response
to increasing doses of phenylephrine, followed by 100 nM angiotensin II. Forces are shown
as a percentage of the maximal response to phenylephrine, which was equal between groups.
The contractile response to angiotensin II was significantly reduced in both the abdominal
aorta (*P<0.05 SMKO, n=5 vs. control, n=5) and mesenteric artery (#P<0.01 SMKO, n=6
vs. control, n=5).
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Figure 3. Microscopic examination and gene expression analysis of an enriched preparations of
pre-glomerular vessels
(A) Photomicrograph (40X) showing a representative pre-glomerular arteriole (Arrow)
purified using the iron oxide-sieving technique. (B) Real time PCR confirmed a significant
enrichment of α-smooth muscle actin (SMA) mRNA in the pre-glomerular vessel isolation
as compared to whole kidney (#P<0.005, n=8). (C) There were no differences in AT1A
receptor mRNA levels in either the whole kidney (n=4) or pre-glomerular vessel preparation
(n=3) between SMKOs and controls (P=NS).
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Figure 4. Intact response to acute vascular angiotensin II response in vivo
Acute vasoconstrictor responses to angiotensin II and epinephrine were measured in
anesthetized mice. Blood pressure was measured continuously while increasing doses of
angiotensin II (0.1–10 μg/kg) were administered at 5–10 minute intervals. No difference was
seen in peak pressor response at any dose between SMKOs and controls (P=NS at 0.1μg/kg,
1μg/kg and 10μg/kg doses, n=6 for both groups).
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Figure 5. VSMC-specific AT1A-receptor deletion does not affect blood pressure response to
chronic angiotensin II administration
Blood pressures were measured in groups of conscious, unrestrained SMKO (open circles
and dashed line) and control (closed circles, solid line) mice using radiotelemetry before and
during chronic infusion of angiotensin II. No differences were seen in MAP between
SMKOs and controls at baseline or during chronic angiotensin II administration (1000ng/kg/
min). There were a total of 11 animals in each experimental group (control and SMKO). In
the first experiment (n=7 per group), blood pressures were measured for 14 days of
angiotensin II infusion. In the second experiment (n=4 per group), technically suitable blood
pressure tracings were available for 21 days of angiotensin II infusion.
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Figure 6. VSMC-specific AT1A-receptor mice have reduced local oxidative stress in the vascular
wall after 4 weeks of angiotensin II-dependent hypertension
Oxidized amino acids in freshly dissected thoracic aorta were quantified by liquid
chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) using
multiple reaction monitoring (MRM) mode in SMKO (n=11) and control (n=13) mice after
4-weeks of angiotensin II administration. Increased levels of both 3-nitrotyrosine (A) and
dityrosine (B) were detected in aortic segments from control mice after angiotensin II
infusion. These increases were significantly attenuated in SMKOs by almost 80% for 3-
nitrotyrosine (7819±1676 vs. 1768±450 μmol/mol tyrosine; **P<0.005) and by almost 50%
for dityrosine (137±27 vs. 74±10μmol/mol tyrosine; #P<0.05).
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Figure 7. Vascular remodeling of aorta is unaffected by VSMC-specific AT1A-receptor deletion
after angiotensin II-induced hypertension
Representative H & E-stained sections taken at 40X of thoracic aortae from control, n=3 (A,
C) and SMKO, n=6 (B, D) mice before (A, B) and after (C, D) 4 weeks of angiotensin II
infusion (n=9 control, n=8 SMKO). (E–F) Aortic medial thickness was quantified using
morphometry. (E) There were no differences in medial thickness at baseline between the
groups; medial thickness increased significantly and to a similar extent in controls and
SMKOs during angiotensin II infusion. (F) Ratios of medial to lumen areas were also similar
in the two groups before and after 4 weeks of angiotensin II infusion. (*P<0.005 vs. Control
Baseline; #P<0.005 vs. SMKO Baseline; ^P<0.05 vs. Control Baseline; +P<0.05 vs. SMKO
Baseline).
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